Skip to search formSkip to main contentSkip to account menu

galunisertib

Known as: 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide 
An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

LY-2157299
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Gens i càncer: avançant cap a la medicina personalitzada: Galunisertib + teràpia anti-PD-L1 com a tractament del càncer uterí
2018
2018
Immunotherapy: Inhibition of TGFβ enhances immune-checkpoint blockade
stromal-derived TGFβ restrains antitumour immunity have now been published in Nature. Both preclinical studies present inhibition… 
2017
2017
Galunisertib crystal form and preparation method therefor and use thereof
Provided are a crystal A of Galunisertib and preparation method therefor and use thereof. The crystal form has favorable… 
2017
2017
Exploring anti-fibrotic drugs : Focusing on an ex vivo model of fibrosis
Als een orgaan door ziekte beschadigd raakt, zet het lichaam een ingewikkeld proces in gang om de schade te herstellen. Soms… 
2017
2017
Abstract 29: Addition of Galunisertib to DC101 increased angiogenesis inhibition and tumor growth control in hepatocellular carcinoma (HCC)
2016
2016
Galunisertib , a TGF-β receptor ( TβR )-I inhibitor , suppresses growth and invasion of an anaplastic thyroid cancer 8505 C cell in vitro and in vivo
Background and objective: The transforming growth factor-beta (TGF-β) signaling pathway is known to play a critical role in… 
2016
2016
A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor (galunisertib) in combination…
2016
2016
ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN…
2016
2016
Abstract 1076: Plasma microRNAs associated with overall survival in patients with hepatocellular carcinoma treated with galunisertib (LY2157299 monohydrate), an inhibitor of transforming growth…
2015
2015
Assessing the Risk of Formation of Potential Genotoxic Degradation Products in a Small-Molecule Kinase Inhibitor Drug Substance and Drug Product
Galunisertib is a kinase inhibitor designed to selectively inhibit TGF-β signaling. Drug substance stress degradation studies…